Loading data for OPTH — first visit, this takes a few seconds.

Optimi Health Corp. (OPTH)

NasdaqCM: OPTH · 即時價格 · USD

4.84

+0.06 (1.26%)

收盤價： Sep 08, 2026, 8:00 PM

4.72

-2.48%

盤後: 7:38 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	4.65
市值	27.7M
營收 (ttm)	176K
淨利（ttm）	-6.9M
	1.59
	-1.45
	n/a
	n/a
P/B (ttm)	2.18
P/S (ttm)	157.76
財報日期	n/a

賣價	4.73
成交量	171,792
20 日平均成交量	73,867
開盤價	4.82
前收盤價	4.78
當日區間	4.68 - 4.96
52 週範圍	4.00 - 6.40
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 OPTH

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical source...

類股 Healthcare

IPO 日期 May 20, 2026

員工 n/a

證券交易所 NasdaqCM

股票代號 OPTH

網站 https://www.optimihealth.ca

完整的公司簡介

財務表現

Optimi Health 在 2025 年的營收為 426.3K，較前一年的 389.85K 增加 9.35%。淨利為 -3.71M，較前期減少 -38.5%。

財務報表

財報驚奇

Optimi Health 已於 Invalid Date 公布季度財報：

營收為 n/a 低於預期 $0, 年增 NaN% 成長.
每股盈餘為低於預期 , 年增 NaN% 成長.

價格為何變動

新聞動態

1 週前 · Market Exclusive

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Aurora Cannabis Urged Shareholders to Reject Curaleaf’s Hostile Takeover Bid Tilray Expanded Global Cannabis Production as International Medical Demand Continues to Grow...

3 週前 · Simply Wall St.

3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now

Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.

3 週前 · Simply Wall St.

Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances

Optimi Health has added financial flexibility to its growth strategy as it advances its MDMA and psilocybin business.

2 月前 · Simply Wall St.

3 Psychedelic Stocks With Potential Clinical Trial Catalysts

Big pharma is funding a field it once dismissed. These three psychedelic stocks carry possible clinical catalysts as the healthcare industry turns to alternative medicines.

3 月前 · Simply Wall St.

Why Optimi’s Ibogaine Initiative Could Open a New Growth Channel

Optimi Health advances ibogaine strategy amid rising regulatory and research support.

第 1 頁，共 2 頁

Optimi Health Corp. (OPTH)